Sign In
Buy ABEO
$6.42
-0.0500 (-0.773%)
At Close: Jul 31, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
12:31pm, Thursday, 23'rd May 2024
NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advise
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
08:45pm, Thursday, 16'th May 2024
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
07:30am, Wednesday, 15'th May 2024
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therape
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Tuesday, 07'th May 2024
CLEVELAND, May 07, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity award
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
06:37pm, Monday, 06'th May 2024
NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
07:30am, Friday, 03'rd May 2024
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
05:50pm, Thursday, 02'nd May 2024
Abeona Therapeutics is a gene therapy company with a lead product candidate, Pz-cel, for recessive epidermolysis bullosa, or RDEB. Pz-cel has shown higher efficacy than the competition in treating lar
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
08:32pm, Wednesday, 01'st May 2024
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) investors concerning
The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
07:11pm, Monday, 29'th Apr 2024
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) on behalf of investors concerni
Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost
05:20pm, Tuesday, 23'rd Apr 2024
Abeona Therapeutics Inc. stock dropped by over half after receiving a Complete Response Letter from the FDA regarding its Biologics License Application for pz-cel. The FDA identified manufacturing iss
Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today?
08:53am, Tuesday, 23'rd Apr 2024
Abeona Therapeutics (NASDAQ: ABEO ) stock is falling on Tuesday after getting a Complete Response Letter ( CRL ) from the Food and Drug Administration (FDA). The CRL from the FDA notes that the regul
US FDA declines to approve Abeona's skin disorder treatment
04:31pm, Monday, 22'nd Apr 2024
Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering condition.
Abeona Therapeutics Provides Regulatory Update on Pz-cel
04:05pm, Monday, 22'nd Apr 2024
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clini
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Monday, 01'st Apr 2024
CLEVELAND, April 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awa
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
07:30am, Monday, 18'th Mar 2024
- FDA completed Pre-License Inspection of Abeona's Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study - - FDA completed Pre-Lice
